Curtains for Tirzepatide Compounding; Redefining Obesity; Menopause and Salary

Watchdoq March 25, 2025
(MedPage Today) -- Last week marked the FDA's deadline for compounders to stop making the obesity drug tirzepatide (Zepbound), leaving some patients unsure where to turn next. (NPR)
Dexcom's investigational 15-day G7 integrated continuous glucose...

Read Full Article